Binds Specifically-identified Oligosaccharide Structure Patents (Class 424/137.1)
-
Patent number: 6759519Abstract: Antibodies against human G-protein chemokine receptor polypeptides, the polypeptides themselves, DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein chemokine receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein chemokine receptor nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.Type: GrantFiled: June 25, 1999Date of Patent: July 6, 2004Assignee: Human Genome Sciences, Inc.Inventors: Yi Li, Steven M. Ruben
-
Patent number: 6692739Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.Type: GrantFiled: August 31, 1999Date of Patent: February 17, 2004Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of The College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Patent number: 6689360Abstract: The present invention relates to antiproliferative genes. More specifically, isolated nucleic acid molecules are provided encoding the human B-cell translocation genes 2 and 3 (BTG-2 and BTG-3). BTG-2 and BTG-3 polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to antibodies to BTG-2 and BGT-3.Type: GrantFiled: April 30, 2001Date of Patent: February 10, 2004Assignee: Human Genome Sciences, Inc.Inventors: Charles A. Kunsch, Arvind Chopra, Craig A. Rosen
-
Patent number: 6686169Abstract: Reagents and methods for the detection of Staphylococcus aureus are provided. The reagents contain an antibody that binds to a capsular polysaccharide of type 5 of Staphylococcus aureus, and can be used in methods for detection of oxacillin resistant Staphylococcus aureus that escapes detection by agglutination in the presence of fibrinogen and antibodies directed against protein A of Staphylococcus.Type: GrantFiled: August 7, 2002Date of Patent: February 3, 2004Assignee: Institut PasteurInventors: Jean-Michel Fournier, Alain Boutonnier
-
Patent number: 6682736Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.Type: GrantFiled: December 23, 1999Date of Patent: January 27, 2004Assignees: Abgenix, Inc., Pfizer Inc.Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
-
Patent number: 6676938Abstract: The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of group B Streptococcus (GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.Type: GrantFiled: May 17, 2001Date of Patent: January 13, 2004Assignee: Chiron S.r.L.Inventors: Giuseppe Teti, Luciano Polonelli
-
Patent number: 6667036Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells, and to treat various conditions involving leukocyte binding via P-selectin glycoprotein ligand.Type: GrantFiled: November 18, 2002Date of Patent: December 23, 2003Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
-
Patent number: 6663863Abstract: The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a site of vascular injury is administered to a subject in need thereof. In another embodiment, a first agent which inhibits recruitment and/or adhesion of neutrophils to a site of vascular injury, and a second agent which inhibits recruitment and/or adhesion of mononuclear cells to a site of vascular injury are administered to a subject in need thereof. In particular embodiments, the agents are antibodies or antigen-binding fragments thereof which bind to CD18 or CCR2.Type: GrantFiled: March 15, 2001Date of Patent: December 16, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Christopher J. Horvath, Patricia E. Rao
-
Patent number: 6663873Abstract: An antigenic preparation for use in the treatment or prevention of Helicobacter infection in a mammalian host, comprises the lipopolysaccharide (LPS) of Helicobacter bacteria, particularly the LPS of H. pylori or H. felis, or an immunogenic fragment thereof.Type: GrantFiled: August 9, 1996Date of Patent: December 16, 2003Assignee: CSLInventors: Christopher Vincent Doidge, Adrian Lee, Fiona Jane Buck, Elizabeth Pietrzykowski, Charles Alexander Quinn, Ian George Barr, Michael John Kleinig
-
Patent number: 6638506Abstract: The present invention is directed to a method of blocking the cytotoxic activity of Fc&ggr;RIII receptor-positive immune cells in a patient with amyotrophic lateral sclerosis using antibodies specific for Fc&ggr;RIII receptor. In one aspect, the antibody may be a monoclonal antibody. In another aspect, the antibody or the monoclonal antibody may be conjugated with a cytotoxic substance. In a further aspect, the antibody binds to the Fc&ggr;RIII receptor, inactivates the receptor, and destroys cellular forms containing the receptor.Type: GrantFiled: September 7, 1999Date of Patent: October 28, 2003Inventor: Walter Schubert
-
Patent number: 6632437Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.Type: GrantFiled: November 15, 1993Date of Patent: October 14, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, John B. Robbins, J. N. Sarvamangala Devi
-
Patent number: 6627196Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.Type: GrantFiled: August 25, 2000Date of Patent: September 30, 2003Assignee: Genentech, Inc.Inventors: Sharon A. Baughman, Steven Shak
-
Patent number: 6613327Abstract: Methods of inhibiting and diagnosing spontaneous abortion in a subject are provided. The subject methods are based, inter alia, on the administration of an agent that inhibits a CD28-C mediated costimulatory signal in a T cell such that spontaneous abortion in the subject is inhibited. The subject methods are also based on the levels of adhesion molecules, inflammatory cytokines, and immune cell surface molecules which are altered in spontaneous abortion.Type: GrantFiled: July 28, 2000Date of Patent: September 2, 2003Assignee: Genetics Institute, Inc.Inventors: Vincent Ling, Gary S. Gray, James C. Keith, Srinivas Maganti
-
Patent number: 6596277Abstract: The present invention provides substantially pure integrins containing a novel &bgr; subunit designated as &bgr;6. The novel &bgr;6 subunit forms heterodimers with &agr;V and &agr;F. Methods of controlling cell adhesion using the &bgr;6-containing integrins are also provided.Type: GrantFiled: February 6, 2002Date of Patent: July 22, 2003Assignee: The Regents of the University of CaliforniaInventors: Dean Sheppard, Robert Pytela
-
Patent number: 6569431Abstract: The invention provides methods and compositions for inhibiting autoantibody binding in demyelinating disease such as multiple sclerosis. The compositions comprise immunoglobulin CDR3 sequences derived from combinatorial phage display libraries selected for high-affinity binding to myelin oligodendrocyte glycoprotein.Type: GrantFiled: July 5, 2001Date of Patent: May 27, 2003Assignee: The Regents of the University of CaliforniaInventors: Hans-Christian von Büdingen, Claude P. Genain, Stephen L. Hauser
-
Patent number: 6537559Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.Type: GrantFiled: September 24, 2001Date of Patent: March 25, 2003Assignee: NABIInventor: Ali Ibrahim Fattom
-
Patent number: 6537550Abstract: The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral cavity and/or pharynx.Type: GrantFiled: September 20, 1999Date of Patent: March 25, 2003Assignee: Immun System I.M.S. ABInventors: Anders Larsson, Hans Kollberg
-
Patent number: 6528269Abstract: The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrPc. These Mabs can be applied to immunoblotting, cell surface immunofluorescent staining and immunohistochemistry at light and electron microscopy. Additionally, these Mabs recognize both the normal (PrPc) and protease-resistant (PrPres) isoforms of PrP. Some Mabs are species restricted, while others react with PrP from a broad range of mammals including mice, humans, monkeys, cows, sheep, squirrels and hamsters. Moreover, several of the Mabs selectively recognize different PrP glycoforms as well as the metabolic fragments of PrPc. These newly generated PrPc antibodies are useful for exploring the biology of PrPc and to establish the diagnosis of prion diseases in both humans and animals.Type: GrantFiled: December 3, 1998Date of Patent: March 4, 2003Assignee: Case Western Reserve UniversityInventors: Man-Sun Sy, Pierluigi Gambetti
-
Patent number: 6514497Abstract: Methods of modulating LERK-2-mediated cell adhesion, as well as methods of modulating angiogenesis and inflammation are described. Also described are agents such as antibodies which can modulate LERK-2-mediated cell adhesion, as well as methods of treating angiogenic diseases and inflammatory diseases.Type: GrantFiled: October 1, 1998Date of Patent: February 4, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Michael J. Briskin, Lily Zou
-
Patent number: 6503509Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: GrantFiled: February 25, 2000Date of Patent: January 7, 2003Assignee: National Jewish Medical & Research CenterInventors: Barbara J. Vilen, John C. Cambier
-
Patent number: 6498237Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: December 24, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 6488929Abstract: A composition, pharmaceutical composition, vaccine and method for the treatment of disseminated candidiasis due to the infection by C. albicans. The composition includes phosphomannan of C. albicans. Monoclonal antibodies for use in passive immunization against candidal infections.Type: GrantFiled: July 12, 1999Date of Patent: December 3, 2002Assignee: Montana State UniversityInventors: Jim E. Cutler, Yongmoon Han
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Patent number: 6451983Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: September 17, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 6448380Abstract: The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumor and tumor regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumor cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: December 13, 2000Date of Patent: September 10, 2002Assignee: Peptech LimitedInventors: Deborah Ann Rathjen, Roger Aston
-
Patent number: 6429295Abstract: The present invention is related with the field of immunology and human medicine, particularly with the generation and selection of a monoclonal antibody (Mab) that recognizes the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tumors. One of the objectives of this invention is to provide a Mab of the IgG1 type that has the characteristic of recognizing with high specificity N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tissues of breast, melanomas and tumors of the liver, stomach, colon, rectum and kidneys. It also has the capacity of producing direct cytolysis of the tumoral cells bearing the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence, thus can be used for the diagnosis and treatment of certain neoplasic diseases.Type: GrantFiled: November 22, 1999Date of Patent: August 6, 2002Assignee: Centro de Inmunologia Molecular (CIM)Inventors: Adriana Carr Pérez, Zaima Mazorra Herrera, Luis Enrique Fernández Molina, Ana Maria Vázquez López, Ailette Mulet Sierra, Rolando Pérez Rodríguez
-
Publication number: 20020098183Abstract: Anti-selectin antibodies for reducing probability of incidence of polytraumatic events, such as organ failure.Type: ApplicationFiled: July 26, 2001Publication date: July 25, 2002Inventors: Ulrich Martin, Anton Haselbeck, Gunther Schumacher, Man Sung Co
-
Patent number: 6416757Abstract: The present invention relates to ligands which bind to human tumour necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified. In preferred forms the ligand binds to TNF in a manner such that the induction of endothelial procoagulant activity of the TNF is inhibited; the binding of TNF to receptors on endothelial cells is inhibited; the induction of fibrin deposition in the tumour and tumour regression activities of the TNF are enhanced; and the cytotoxicity and receptor binding activities of the TNF are unaffected or enhanced on tumour cells. The ligand is preferably an antibody, F(ab) fragment, single domain antibody (dABs) single chain antibody or a serum binding protein. It is preferred, however, that the ligand is a monoclonal antibody or F(ab) fragment thereof.Type: GrantFiled: July 30, 1999Date of Patent: July 9, 2002Assignee: Peptide Technology Ltd.Inventors: Deborah Ann Rathjen, Roger Aston
-
Publication number: 20020086012Abstract: A soluble bispecific fusion protein consisting of a) a binding domain which recognizes a specific surface molecule on a target cell, covalently linked to b) a domain capable of stimulating T cell proliferation, can be used for a specific costimulation of a T cell directed against said target cell.Type: ApplicationFiled: August 31, 1999Publication date: July 4, 2002Inventors: WINFRIED WELS, BERNHARD GERSTMAYER
-
Publication number: 20020068058Abstract: The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.Type: ApplicationFiled: December 21, 2001Publication date: June 6, 2002Inventors: Claude P. Genain, Stephen L. Hauser
-
Publication number: 20020068329Abstract: The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.Type: ApplicationFiled: December 12, 1997Publication date: June 6, 2002Applicant: Behringwerke AktiengesellschaftInventors: MATHIAS GEHRMANN, GERHARD SEEMANN, KLAUS BOSSLET, JORG CZECH
-
Patent number: 6391301Abstract: The present invention relates to a novel composition for identifying and suppressing the growth of tumor cells, which comprises antibodies which react with proteins having N-glycosidically bonded saccharides.Type: GrantFiled: August 16, 1999Date of Patent: May 21, 2002Assignee: Forschungszentrum Karlsruhe GmbHInventors: Jonathan Sleeman, Helmut Ponta, Peter Herrlich, Kim Untae
-
Patent number: 6376203Abstract: Mouse is immunized with an antigen of a lipid fraction originating from Mycoplasma fermentans. Its spleen cells are fused with mouse myeloma cells to prepare hybridomas. A hybridoma is selected, which produces a monoclonal antibody having reaction specificity to GGPL-III that is a phosphocholine-containing glycoglycerolipid specific to Mycoplasma fermentans. Mycoplasma fermentans is detected by using the obtained antibody.Type: GrantFiled: July 8, 1999Date of Patent: April 23, 2002Assignee: Seikagaku CorporationInventors: Kazuhiro Matsuda, Naoki Yamamoto
-
Publication number: 20020031511Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: ApplicationFiled: July 20, 2001Publication date: March 14, 2002Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Publication number: 20020031528Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.Type: ApplicationFiled: September 24, 2001Publication date: March 14, 2002Inventor: Ali Ibrahim Fattom
-
Patent number: 6350449Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like, as well as antibodies to these conjugate vaccines. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 1999Date of Patent: February 26, 2002Assignee: Baxter International Inc.Inventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6333033Abstract: The invention provides methods and compositions for inhibiting pathogenic binding of an pathogenic autoantibody to a myelin oligodendrocyte glycoprotein (MOG) autoantigen and screening for inhibitors of pathogenic binding of an autoantibody to a MOG autoantigen.Type: GrantFiled: August 26, 1999Date of Patent: December 25, 2001Assignee: The Regents of the University of CaliforniaInventors: Claude P. Genain, Stephen L. Hauser
-
Publication number: 20010051717Abstract: Methods of isolating &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, or of detecting the presence of &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms in a sample, utilizing binding agents for &bgr;(1-3)-glucan, such as LacCer, GalCer, globotriaosylceramide and asialoganglioside-GM1, are described. Methods of diagnosing fungal infection, by detecting &bgr;(1-3)-glucan or &bgr;(1-3)-glucan-containing organisms, are also described. Antibodies and kits useful in the methods are also disclosed.Type: ApplicationFiled: June 19, 2001Publication date: December 13, 2001Applicant: Collaborative Group, Ltd.Inventors: Eric M. Wakshull, William M. Mackin, Janet W. Zimmerman, Leslie W. Fisette
-
Patent number: 6312694Abstract: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolaminie, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.Type: GrantFiled: July 12, 1999Date of Patent: November 6, 2001Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Sophia Ran
-
Patent number: 6309639Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.Type: GrantFiled: August 9, 2000Date of Patent: October 30, 2001Assignee: The Board of Regents of the University of OklahomaInventors: Richard D. Cummings, Kevin L. Moore, Rodger P. McEver
-
Patent number: 6303120Abstract: The present invention provides a method of synthesizing an allyl pentasaccharide having the structure: as well as related oligosaccharide ceramides and other glycoconjugates useful as vaccines for inducing antibodies to epithelial cancer cells in an adjuvant therapy therefor, and in a method for preventing recurrence of epithelial cancer.Type: GrantFiled: July 24, 1995Date of Patent: October 16, 2001Assignee: Memorial Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Victor Behar, Kenneth O. Lloyd
-
Patent number: 6294167Abstract: The invention concerns medicaments containing antibodies which have at least one specificity and detect the MHCII antigen of a patient to be treated. The invention further concerns antibodies with two or more specificities which detect the MHCII antigen of a patient, and diagnostic compositions containing these antibodies.Type: GrantFiled: November 23, 1998Date of Patent: September 25, 2001Assignee: GSF-Forschungszentrum fur Umwelt und Gesundheit GmbHInventors: Horst Lindhofer, Stefan Thierfelder
-
Patent number: 6294177Abstract: A negatively-charged S. aureus antigen contains &bgr;-hexosamine as a major carbohydrate component. S. aureus strains that carry the antigen account for nearly all of the clinically significant strains of S. aureus that are not Type 5 or Type 8 strains. The antigen can be used in combination with S. aureus Type 5 polysaccharide antigen and S. aureus Type 8 polysaccharide antigen to provide nearly 100% coverage of S. aureus infection. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing S. aureus infection. A whole cell vaccine of cells that contain the antigen is particularly useful in the treatment of mastitis.Type: GrantFiled: May 10, 1999Date of Patent: September 25, 2001Assignee: NABIInventor: Ali Ibrahim Fattom
-
Patent number: 6291649Abstract: An antigen which, as its major immunizing component, comprises a determinant of an adhesin polypeptide or an immunogenically active subsequence thereof or a precursor therefor which is convertible to an immunogenically active form, antibodies against which determinant react with the adhesin polypeptide produced by pathogenic adhesin-forming bacteria which adhere to mammalian tissue, antibodies against such antigen, and DNA expressing, as a principal gene product thereof, such antigen.Type: GrantFiled: May 11, 1998Date of Patent: September 18, 2001Assignee: Symbicom AktiebolagInventors: Frederik Carl Lindberg, Björn Olof Lund, Britt Monika B{dot over (a)}ga, Mari Elisabet Norgen, Mikael Göransson, Bernt Eric Uhlin, Jan Staffan Normark, David Lee Lark
-
Patent number: 6238668Abstract: The present invention provides processes for the preparation of the KH-1 and N3 antigens, as well as related analgoues thereof, which are useful as anticancer therapeutics. The present invention also provides various intermediates useful in the preparation of KH-1 and N3 and analogues thereof. Additionally, the invention provides various compositions comprising any of the analogues of KH-1 and N3 available through the methods of the invention and pharmaceutical carriers useful in the treatment of subjects suffering from various forms of epithelial cancer.Type: GrantFiled: January 13, 1998Date of Patent: May 29, 2001Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, Prashant P. Deshpande, In Jong Kim, Philip Livingston, Hyun Jin Kim, Ragupathi Govindaswami, Tae Kyo Park
-
Patent number: 6228598Abstract: Methods aiding in the diagnosis of certain immune-mediated, motor-sensory polyneuropathies, both chronic and acute, by assessing the amount of antibodies to heparan sulfate glycosaminoglycan, either acetylated or non-acetylated, in a test sample, are disclosed, as are kits that can be used in the methods.Type: GrantFiled: October 2, 1998Date of Patent: May 8, 2001Assignee: Washington UniversityInventor: Alan Pestronk
-
Patent number: 6204366Abstract: A reshaped human antibody or reshaped human antibody fragment having specificity for human polymorphic epithelial mucin (PEM) is produced by transferring the complementarity determining regions (CDRS) from a murine anti-HMFG hybridoma cell line HMFG1 into a human antibody variable region framework. The reshaped molecule can be used in the treatment or diagnosis of cancer.Type: GrantFiled: May 7, 1993Date of Patent: March 20, 2001Assignee: Unilever Patent Holdings B.V.Inventor: Martine Elisa Verhoeyen
-
Patent number: 6187308Abstract: Monoclonal antibodies and method for ameliorating an immune response disorder. The monoclonal antibodies are specific for an epitope present on the leukocyte adhesion receptor &bgr;-chain.Type: GrantFiled: November 20, 1998Date of Patent: February 13, 2001Assignee: The Johns Hopkins University School of MedicineInventor: James E. Hildreth
-
Patent number: 6174691Abstract: The peptide EPPT (Glu-Pro-Pro-Thr)(SEQ I YD NO:1) selectively binds a mucin expressed by epithelial tumors. It may be incorporated into larger molecules, such as, peptides consisting of the sequence EPPT and further amino acids to form a peptide of up to 30 amino acids, and may be radiolabelled or used to guide toxins, etc. to cells expressing the mucin.Type: GrantFiled: August 7, 1998Date of Patent: January 16, 2001Assignee: Cancer Therapeutics LimitedInventor: Nigel Stephen Courtenay-Luck